Dr. Copeland on the Role of Chemotherapy in Ovarian Cancer

Larry J. Copeland, MD
Published: Friday, Jan 17, 2020



Larry J. Copeland, MD, professor, Obstetrics & Gynecology, College of Medicine, The Ohio State University Comprehensive Cancer Center–James, discusses the role of chemotherapy in ovarian cancer.

Platinum-based chemotherapy is a standard frontline therapy, says Copeland. However, there is debate as to the optimal delivery method. Intravenous, intraperitoneal, and dose-dense delivery are all potential options for patients.

Additionally, whether to use bevacizumab (Avastin) as up-front therapy or as secondary treatment remains an unanswered question, says Copeland. Moreover, PARP inhibitors have also been added to the frontline space and may complicate treatment decisions, explains Copeland. Ongoing clinical trials may help clarify the relative value of these available options, concludes Copeland.
SELECTED
LANGUAGE


Larry J. Copeland, MD, professor, Obstetrics & Gynecology, College of Medicine, The Ohio State University Comprehensive Cancer Center–James, discusses the role of chemotherapy in ovarian cancer.

Platinum-based chemotherapy is a standard frontline therapy, says Copeland. However, there is debate as to the optimal delivery method. Intravenous, intraperitoneal, and dose-dense delivery are all potential options for patients.

Additionally, whether to use bevacizumab (Avastin) as up-front therapy or as secondary treatment remains an unanswered question, says Copeland. Moreover, PARP inhibitors have also been added to the frontline space and may complicate treatment decisions, explains Copeland. Ongoing clinical trials may help clarify the relative value of these available options, concludes Copeland.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x